NRNP 6635 PSYCHOPATHOLOGY MIDTERM EXAM STUDY
GUIDE 2026/2027 | Diagnostic Reasoning | Walden
University | Pass Guaranteed - A+ Graded
Section 1: Neurobiology of Psychiatric Disorders (Q1-15)
Q1. A PMHNP student is reviewing the dopamine hypothesis of schizophrenia.
Which statement accurately describes the current understanding of dopamine's
role in psychotic symptoms?
A. Hypodopaminergic activity in the mesolimbic pathway causes positive symptoms
B. Hyperdopaminergic activity in the mesolimbic pathway and hypodopaminergic
activity in the mesocortical pathway contribute to symptom expression
C. Dopamine has no role in schizophrenia; serotonin is the primary neurotransmitter
D. Dopamine excess occurs uniformly throughout all brain regions
B. Hyperdopaminergic activity in the mesolimbic pathway and hypodopaminergic
activity in the mesocortical pathway contribute to symptom expression [CORRECT]
Rationale: The revised dopamine hypothesis states mesolimbic hyperdopaminergia
drives positive symptoms while mesocortical hypodopaminergia contributes to
negative/cognitive symptoms. Option A reverses the pathways; option C ignores
dopamine's established role; option D oversimplifies regional differences.
Correct Answer: B
Q2. A client with major depressive disorder is prescribed a selective serotonin
reuptake inhibitor (SSRI). The PMHNP explains that SSRIs primarily exert their
therapeutic effect by:
A. Increasing serotonin synthesis in the raphe nuclei
B. Blocking reuptake of serotonin at the presynaptic membrane, increasing synaptic
availability
,C. Directly stimulating postsynaptic serotonin receptors
D. Inhibiting monoamine oxidase breakdown of serotonin
B. Blocking reuptake of serotonin at the presynaptic membrane, increasing synaptic
availability [CORRECT]
Rationale: SSRIs block the serotonin transporter (SERT), preventing reuptake and
increasing 5-HT in the synaptic cleft. Option A describes precursor loading; option C
describes direct agonists; option D describes MAOIs.
Correct Answer: B
Q3. The PMHNP is evaluating a client with generalized anxiety disorder who has
not responded to SSRIs. The prescriber considers a medication targeting the
GABA system. Which mechanism best explains GABA's role in anxiety reduction?
A. GABA-A receptor antagonism increases neuronal excitability
B. GABA-A receptor agonism enhances chloride ion influx, producing neuronal
hyperpolarization and reduced anxiety
C. GABA-B receptor activation increases dopamine release
D. GABA is excitatory in the amygdala and increases fear responses
B. GABA-A receptor agonism enhances chloride ion influx, producing neuronal
hyperpolarization and reduced anxiety [CORRECT]
Rationale: GABA is the primary inhibitory neurotransmitter; GABA-A agonists
(benzodiazepines) increase Cl⁻ influx, hyperpolarizing neurons and reducing anxiety.
Option A describes antagonist effects; option C is incorrect; option D is opposite of
GABA's function.
Correct Answer: B
Q4. A PMHNP student is studying the role of glutamate in schizophrenia. Which
statement accurately reflects current neurobiological understanding?
A. NMDA receptor hypofunction may contribute to both positive and negative
symptoms
,B. Glutamate excess is the sole cause of schizophrenia
C. Glutamate receptors are only located in the peripheral nervous system
D. NMDA agonists are first-line treatments for schizophrenia
A. NMDA receptor hypofunction may contribute to both positive and negative
symptoms [CORRECT]
Rationale: The glutamate hypothesis posits NMDA receptor hypofunction
(particularly on GABA interneurons) disrupts cortical circuitry, contributing to
schizophrenia symptoms. Option B oversimplifies etiology; option C is anatomically
incorrect; option D is wrong as NMDA modulators are investigational.
Correct Answer: A
Q5. A client with treatment-resistant depression is prescribed a medication that
modulates the norepinephrine-dopamine disinhibition (NDDI) mechanism.
Which medication class works through this mechanism?
A. Selective serotonin reuptake inhibitors
B. Serotonin-norepinephrine reuptake inhibitors
C. Norepinephrine-dopamine reuptake inhibitors (NDRIs) such as bupropion
D. Tricyclic antidepressants
C. Norepinephrine-dopamine reuptake inhibitors (NDRIs) such as bupropion
[CORRECT]
Rationale: Bupropion inhibits reuptake of norepinephrine and dopamine without
significant serotonergic effects, classifying it as an NDRI. Options A, B, and D involve
serotonin reuptake inhibition as primary or significant mechanisms.
Correct Answer: C
Q6. The PMHNP is reviewing neuroimaging findings in major depressive disorder.
Which structural brain change is most consistently observed?
A. Hippocampal enlargement and increased prefrontal cortex volume
B. Reduced hippocampal volume, decreased prefrontal cortex thickness, and altered
, amygdala activity
C. Cerebellar atrophy as the primary finding
D. No structural changes are observed in depression; only functional changes occur
B. Reduced hippocampal volume, decreased prefrontal cortex thickness, and altered
amygdala activity [CORRECT]
Rationale: Meta-analyses consistently show reduced hippocampal volume, PFC
thinning, and amygdala hyperactivity in MDD. Option A reverses the findings; option
C is not a primary finding; option D is incorrect as structural changes are well-
documented.
Correct Answer: B
Q7. A PMHNP student asks about the role of the HPA axis in psychiatric disorders.
Which statement best describes HPA axis dysregulation in major depressive
disorder?
A. Chronic HPA axis suppression with low cortisol levels
B. HPA axis hyperactivity with elevated cortisol, blunted negative feedback, and
potential hippocampal damage
C. The HPA axis is not involved in mood disorders
D. HPA axis function is enhanced with increased glucocorticoid receptor sensitivity
B. HPA axis hyperactivity with elevated cortisol, blunted negative feedback, and
potential hippocampal damage [CORRECT]
Rationale: MDD is associated with chronic HPA activation, elevated cortisol, impaired
negative feedback (dexamethasone non-suppression), and hippocampal
neurotoxicity. Option A describes suppression; option C is incorrect; option D is
opposite (receptor resistance occurs).
Correct Answer: B
Q8. A client with bipolar disorder is prescribed lithium. The PMHNP explains that
lithium's mechanism of action involves modulation of which intracellular
signaling pathway?
GUIDE 2026/2027 | Diagnostic Reasoning | Walden
University | Pass Guaranteed - A+ Graded
Section 1: Neurobiology of Psychiatric Disorders (Q1-15)
Q1. A PMHNP student is reviewing the dopamine hypothesis of schizophrenia.
Which statement accurately describes the current understanding of dopamine's
role in psychotic symptoms?
A. Hypodopaminergic activity in the mesolimbic pathway causes positive symptoms
B. Hyperdopaminergic activity in the mesolimbic pathway and hypodopaminergic
activity in the mesocortical pathway contribute to symptom expression
C. Dopamine has no role in schizophrenia; serotonin is the primary neurotransmitter
D. Dopamine excess occurs uniformly throughout all brain regions
B. Hyperdopaminergic activity in the mesolimbic pathway and hypodopaminergic
activity in the mesocortical pathway contribute to symptom expression [CORRECT]
Rationale: The revised dopamine hypothesis states mesolimbic hyperdopaminergia
drives positive symptoms while mesocortical hypodopaminergia contributes to
negative/cognitive symptoms. Option A reverses the pathways; option C ignores
dopamine's established role; option D oversimplifies regional differences.
Correct Answer: B
Q2. A client with major depressive disorder is prescribed a selective serotonin
reuptake inhibitor (SSRI). The PMHNP explains that SSRIs primarily exert their
therapeutic effect by:
A. Increasing serotonin synthesis in the raphe nuclei
B. Blocking reuptake of serotonin at the presynaptic membrane, increasing synaptic
availability
,C. Directly stimulating postsynaptic serotonin receptors
D. Inhibiting monoamine oxidase breakdown of serotonin
B. Blocking reuptake of serotonin at the presynaptic membrane, increasing synaptic
availability [CORRECT]
Rationale: SSRIs block the serotonin transporter (SERT), preventing reuptake and
increasing 5-HT in the synaptic cleft. Option A describes precursor loading; option C
describes direct agonists; option D describes MAOIs.
Correct Answer: B
Q3. The PMHNP is evaluating a client with generalized anxiety disorder who has
not responded to SSRIs. The prescriber considers a medication targeting the
GABA system. Which mechanism best explains GABA's role in anxiety reduction?
A. GABA-A receptor antagonism increases neuronal excitability
B. GABA-A receptor agonism enhances chloride ion influx, producing neuronal
hyperpolarization and reduced anxiety
C. GABA-B receptor activation increases dopamine release
D. GABA is excitatory in the amygdala and increases fear responses
B. GABA-A receptor agonism enhances chloride ion influx, producing neuronal
hyperpolarization and reduced anxiety [CORRECT]
Rationale: GABA is the primary inhibitory neurotransmitter; GABA-A agonists
(benzodiazepines) increase Cl⁻ influx, hyperpolarizing neurons and reducing anxiety.
Option A describes antagonist effects; option C is incorrect; option D is opposite of
GABA's function.
Correct Answer: B
Q4. A PMHNP student is studying the role of glutamate in schizophrenia. Which
statement accurately reflects current neurobiological understanding?
A. NMDA receptor hypofunction may contribute to both positive and negative
symptoms
,B. Glutamate excess is the sole cause of schizophrenia
C. Glutamate receptors are only located in the peripheral nervous system
D. NMDA agonists are first-line treatments for schizophrenia
A. NMDA receptor hypofunction may contribute to both positive and negative
symptoms [CORRECT]
Rationale: The glutamate hypothesis posits NMDA receptor hypofunction
(particularly on GABA interneurons) disrupts cortical circuitry, contributing to
schizophrenia symptoms. Option B oversimplifies etiology; option C is anatomically
incorrect; option D is wrong as NMDA modulators are investigational.
Correct Answer: A
Q5. A client with treatment-resistant depression is prescribed a medication that
modulates the norepinephrine-dopamine disinhibition (NDDI) mechanism.
Which medication class works through this mechanism?
A. Selective serotonin reuptake inhibitors
B. Serotonin-norepinephrine reuptake inhibitors
C. Norepinephrine-dopamine reuptake inhibitors (NDRIs) such as bupropion
D. Tricyclic antidepressants
C. Norepinephrine-dopamine reuptake inhibitors (NDRIs) such as bupropion
[CORRECT]
Rationale: Bupropion inhibits reuptake of norepinephrine and dopamine without
significant serotonergic effects, classifying it as an NDRI. Options A, B, and D involve
serotonin reuptake inhibition as primary or significant mechanisms.
Correct Answer: C
Q6. The PMHNP is reviewing neuroimaging findings in major depressive disorder.
Which structural brain change is most consistently observed?
A. Hippocampal enlargement and increased prefrontal cortex volume
B. Reduced hippocampal volume, decreased prefrontal cortex thickness, and altered
, amygdala activity
C. Cerebellar atrophy as the primary finding
D. No structural changes are observed in depression; only functional changes occur
B. Reduced hippocampal volume, decreased prefrontal cortex thickness, and altered
amygdala activity [CORRECT]
Rationale: Meta-analyses consistently show reduced hippocampal volume, PFC
thinning, and amygdala hyperactivity in MDD. Option A reverses the findings; option
C is not a primary finding; option D is incorrect as structural changes are well-
documented.
Correct Answer: B
Q7. A PMHNP student asks about the role of the HPA axis in psychiatric disorders.
Which statement best describes HPA axis dysregulation in major depressive
disorder?
A. Chronic HPA axis suppression with low cortisol levels
B. HPA axis hyperactivity with elevated cortisol, blunted negative feedback, and
potential hippocampal damage
C. The HPA axis is not involved in mood disorders
D. HPA axis function is enhanced with increased glucocorticoid receptor sensitivity
B. HPA axis hyperactivity with elevated cortisol, blunted negative feedback, and
potential hippocampal damage [CORRECT]
Rationale: MDD is associated with chronic HPA activation, elevated cortisol, impaired
negative feedback (dexamethasone non-suppression), and hippocampal
neurotoxicity. Option A describes suppression; option C is incorrect; option D is
opposite (receptor resistance occurs).
Correct Answer: B
Q8. A client with bipolar disorder is prescribed lithium. The PMHNP explains that
lithium's mechanism of action involves modulation of which intracellular
signaling pathway?
